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Abstract
Background
E-cigarettes are currently being debated regarding their possible role in smoking cessation
and as they are becoming increasingly popular, the research to date requires investigation.
Objectives
To investigate whether the use of e-cigarettes is associated with smoking cessation or re-
duction, and whether there is any difference in efficacy of e-cigarettes with and without nico-
tine on smoking cessation.
Data Sources
A systematic review of articles with no limit on publication date was conducted by searching
PubMed, Web of Knowledge and Scopus databases.
Methods
Published studies, those reported smoking abstinence or reduction in cigarette consump-
tion after the use of e-cigarettes, were included. Studies were systematically reviewed, and
meta-analyses were conducted using Mantel-Haenszel fixed-effect and random-effects
models. Degree of heterogeneity among studies and quality of the selected studies
were evaluated.
Results
Six studies were included involving 7,551 participants. Meta-analyses included 1,242 partici-
pants who had complete data on smoking cessation. Nicotine filled e-cigarettes were more ef-
fective for cessation than those without nicotine (pooled Risk Ratio 2.29, 95%CI 1.05-4.97).
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Amongst 1,242 smokers, 224 (18%) reported smoking cessation after using nicotine-enriched
e-cigarettes for a minimum period of six months. Use of such e-cigarettes was positively asso-
ciated with smoking cessation with a pooled Effect Size of 0.20 (95%CI 0.11-0.28). Use of
e-cigarettes was also associated with a reduction in the number of cigarettes used.
Limitations
Included studies were heterogeneous, due to different study designs and gender variation.
Whilst we were able to comment on the efficacy of nicotine vs. non-nicotine e-cigarettes for
smoking cessation, we were unable to comment on the efficacy of e-cigarettes vs. other in-
terventions for cessation, given the lack of comparator groups in the studies included in this
meta-analysis.
Conclusions
Use of e-cigarettes is associated with smoking cessation and reduction. More randomised
controlled trials are needed to assess effectiveness against other cessation methods.
Introduction
Smoking accounts for more deaths and diseases worldwide than any other modifiable risk fac-
tors.[1, 2] Literature suggests that approximately three quarters of smokers want to quit; how-
ever, smoking is highly addictive and smoking cessation is difficult with frequent relapses
common amongst those who try to quit.[1] There is ongoing research on the effectiveness of
various smoking cessation interventions. Nicotine replacement therapy (NRT), bupropion,
varenicline and cytisine medications have been shown to improve the likelihood of quitting,
with varenicline showing the greatest benefit. However, these products have relatively low
consumer appeal and product satisfaction.[3, 4] Evidence suggests that psychosocial smoking
cessation interventions such as behavioural counselling, telephone support and self-help inter-
ventions are effective; behavioural interventions combined with pharmacotherapy increase the
success rate of quitting.[5, 6]
Over recent years, electronic cigarettes (e-cigarettes) have gained the attention of smokers
due to their ability to closely simulate the aesthetic and behavioural experience of smoking, as
well as delivering a dose of nicotine without involving the combustion of tobacco. E-cigarettes
may, therefore, have potential roles in both smoking cessation and tobacco harm reduction.[7,
8] In our recent literature review on the e-cigarette phenomenon, we found there was a need
for further research to answer key questions about the safety, patterns of use, effectiveness for
smoking cessation and regulatory issues associated with the use of e-cigarettes.[9]
Although the vast majority of e-cigarette users are current smokers, they appear to fall into
two distinct groups—those using them to quit smoking and those using them recreationally with
no intention of quitting.[9, 10] The presence of recreational e-cigarettes users has raised con-
cerns whether e-cigarettes act as genuine smoking cessation aids or merely ‘bridging’ products,
which perpetuate smokers’ nicotine addictions by enabling them to smoke in environments
where smoking has been banned, or ‘gateway’ products which hook first time users into nico-
tine.[10, 11] These concerns have arisen from the studies on initial use of e-cigarettes, however,
it is also feasible that entrenched smokers may be able to reduce their tobacco use by substituting
e-cigarettes for cigarettes. In terms of the safety of e-cigarettes, while there have been no data on
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their long term health effects, a substantial body of research now exists reporting mixed findings
about the toxicity of their refill solutions, with the variation apparently due to divergent testing
methods.[12–14] Similarly, there is conflicting evidence as to whether e-cigarettes are effective
for smoking cessation and this creates a pressing dilemma for regulatory authorities which seek
to minimise harms without stifling a potentially beneficial product.[10, 11]
Therefore, clarity is required on two key issues; whether they are safe, and whether they are
effective aids for smoking cessation. If scientific evidence demonstrates that e-cigarettes are
safe and effective for smoking cessation, they are likely to become additional tools for smoking
cessation programs and tobacco harm reduction strategies. On the other hand, if they are
shown to be unsafe or ineffective for smoking cessation, regulatory decisions which limit their
sales and use may be expedited to minimise their use as bridging products which perpetuate or
initiate nicotine addiction. Quality evidence to inform these decisions is scarce and a compre-
hensive systematic review and meta-analysis on this issue has not been undertaken so far.
Therefore, the objective of this paper was to conduct a systematic review and meta-analyses to
investigate whether long-term use of e-cigarettes among current smokers was associated with
smoking cessation or reduction, and whether there is any difference in efficacy of e-cigarettes
with and without nicotine on smoking cessation.
Methods
Study selection
The team agreed on the search terms, scope and approach for this systematic review and meta-
analyses. Two researchers conducted a comprehensive literature search according to the meth-
od recommended by the Cochrane Collaboration. Selected studies were evaluated using the
Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines.
[15, 16] In line with the objective of this systematic review, use of e-cigarettes was selected as
the main exposure variable and smoking cessation as the predominant outcome variable. We
reviewed published studies including randomised controlled trials (RCTs), cohort, case-control
and cross-sectional studies, if they assessed the efficacy of e-cigarettes in achieving smoking ab-
stinence or reduction in cigarette consumption, among current smokers who had used the de-
vices for six months or more. Studies with additional outcomes pertaining to smoking
reduction were permitted, while those with primary endpoints concerning other issues such as
attenuation of withdrawal symptoms were excluded.
Search strategy
Fig 1 depicts the search strategy used and number of records identified and excluded at each
step. PubMed, Web of Knowledge and Scopus databases were searched using the following
terms: “electronic cigarettes OR e-cigarettes” AND “smoking cessation OR quit smoking”. Fur-
ther search criteria were studies published in English and conducted on humans. There was no
limit on publication date. The databases were last searched in May, 2014. The combined search
revealed 718 articles, from which 249 were removed as duplicates. Titles and abstracts were re-
viewed for the remaining articles, from which 434 were excluded and 35 full-text articles were
reviewed against the inclusion criteria.
Study selection and data extraction
Nine studies were initially included, but three were subsequently excluded because they investi-
gated smoking cessation in a schizophrenic group of patients.[17–19] These exclusions were
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made on the basis of inadequate outcome data and/or study populations that were either in-
congruent or overlapping with the other included studies.[20–25]
Data analyses
Meta-analyses were performed using the metan Stata statistical program (version 13, Stata-
Corp, College Station, TX), and were conducted with two objectives: 1) to compare the effect of
e-cigarettes with and without nicotine on abstinence from tobacco smoking in order to evaluate
the device’s associated placebo effect, and 2) to evaluate the long-term association between the
use of e-cigarettes (i.e., after at least six months use) and smoking cessation. This was
Fig 1. Search strategy for identification and selection of studies investigating the efficacy of electronic cigarettes for smoking cessation and
reduction (PRISMA flowchart).
doi:10.1371/journal.pone.0122544.g001
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investigated by calculating a pooled proportion of quitters as reported in the meta-analysed
studies. Subjects lost to follow up were counted as smokers (consistent with intention-to-treat
methods). In addition to these objectives, the quality of included studies was also assessed.
Findings from the two included RCTs by Bullen et al. and Caponnetto et al. were meta-
analysed to answer the study’s first objective.[20, 21] Meta-analyses were performed using a
Mantel-Haenszel fixed effects model.[26] The pooled risk ratio (RR) with 95% confidence in-
terval (CI) was calculated. The RR was defined as the ratio of risk of abstinence from smoking
among those exposed to nicotine enriched e-cigarettes and the risk of abstinence among those
using non-nicotine enriched e-cigarettes. If the value of 1 was not within the 95% CI, the RR
was statistically significant at the 5% level (p<0.05). The I2 statistic was calculated to demon-
strate the degree of heterogeneity—that is, the percentage of variation across studies that is not
due to chance.[27]
For the second objective, an overall proportion of abstinence from the set of proportions re-
ported in each of the six included studies was calculated using a random-effects meta-analysis
model using DerSimonian and Laird method.[28] This method incorporates an estimate of the
between-study variation into both the study weights and the standard error of the estimate of
the common effect. The precision of an estimate from each included study was represented by
the inverse of the variance of the outcome pooled across all participants.[29] Less precise esti-
mates have larger variances, so the inverse of variance is smaller for studies with less precise es-
timates. The fixed effects model was utilised when running the sub analyses by study designs.
The pooled effect size (ES) (estimated by the pooled proportion) with 95% CI was calculated. If
the value of the pooled proportion ‘zero’ was not within the 95% CI, the ES was statistically sig-
nificant at the 5% level (P<0.05).
Quality assessment
The quality of the studies included in the meta-analyses was assessed at the entire study level as
well as at the outcome level, in the manner recommended by the Cochrane Collaboration
using the Downs and Black instrument.[15, 30] For RCTs, the checklist produced by van
Tulder et al. as part of the Cochrane Back Review Group was used, while the checklist provided
by Downs and Black was used to assess bias in the observational studies.[30, 31] These tools
were simultaneously used to make an assessment of the risk of bias affecting the findings of the
studies. We also examined whether all outcomes were reported and reasons behind any exclu-
sion. The quality of the studies was independently assessed by three researchers. The degree of
agreement between researchers was calculated together with Cohen’s Kappa coefficient to mea-
sure inter-rater agreement.
Results
Characteristics of included studies
Table 1 presents summary data and key findings for all six included studies.
Study type
Of the six included studies, two were RCTs, two were cross-sectional studies, and two were pro-
spective cohort studies.[20–25]
Participants
The combined sample size from the selected studies was 7,551. Recruitment methods were sim-
ilar across most studies, and used either newspaper advertisements, emails to product users or
E-Cigarettes for Smoking Cessation
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national health agency-run surveys to recruit members of the public.[20–25] Two studies con-
ducted comprehensive randomisation processes of participants.[20, 21] Inclusion and exclu-
sion criteria were also largely common to all selected studies. The predominant inclusion
criteria were adult current smokers (although exact definition of smoking status varied), while
the main exclusion criteria were comorbid cardiovascular disease, diabetes, major depression
and other psychiatric disorders.
Smoking status and quit intentions
All participants in the included studies were current smokers.[20–25] In two of the studies par-
ticipants were not intending to quit smoking prior to use of an e-cigarette,[21, 23] while re-
maining studies’ participants were either intending to quit or had mixed intentions.[20, 22, 24,
25]There was slight variation between the studies in the way smoking status was defined. Most
studies defined current smokers as those who had smoked at least 10 cigarettes per day for a pe-
riod of years.[20, 21, 23] Two studies did not explicitly define current smoking status, however,
participants self-reported themselves as either daily or occasional smokers.[22, 25] Finally, Sie-
gel et al. defined it as participants having smoked100 cigarettes in their lifetime.[24] Recruit-
ment criteria regarding participants’ intention to quit varied across studies; two studies
recruited those who were intending to quit, two not intending to quit, and the remaining two
studies’ participants had mixed intentions.
Intervention
The intervention implemented in three of the six studies was ad lib use of e-cigarettes, which
were provided to participants for the duration of the study period.[20, 21, 23] The remaining
studies were cross-sectional and cohort in design, and did not include an intervention, but sim-
ilarly investigated participants’ ad lib use of e-cigarettes over the study period.[22, 24, 25]
Comparator
Two of the selected studies (both RCTs) included formal comparator groups or interventions.
[20, 21] One used groups assigned to nicotine patches and placebo e-cigarettes as comparators,
[20] while the other just used a group assigned to placebo e-cigarettes as a comparator.[21]
One of the cross-sectional studies compared smoking cessation rates among e-cigarette users
to those using NRT and those quitting unaided.[25]
Outcomes
The primary outcome for five of the studies was either abstinence from smoking at the end of
the designated study period or reduction in smoking (as measured by number of cigarettes per
day).[20, 21, 23–25] The remaining study primarily investigated longitudinal usage patterns of
e-cigarettes but measured smoking cessation and reduction as a secondary outcome.[22] Ad-
verse events and withdrawal symptoms were specifically assessed in both RCTs [20, 21] and in
one cohort study.[24]
Definition of smoking cessation
Studies defined smoking cessation in one of two ways. Three studies defined it as complete
self-reported abstinence from tobacco cigarettes over a given portion of the follow-up period,
verified by an exhaled carbon monoxide (eCO) measurement of either7ppm or10ppm.
[20, 21, 23] The remaining studies did not explicitly define smoking cessation; but similar to
E-Cigarettes for Smoking Cessation
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the others, implied complete self-reported abstinence from tobacco without the requirement
for biochemical verification.[22, 24, 25]
Efficacy of e-cigarettes with and without nicotine on smoking cessation
Number of those who stopped and did not stop smoking among users of nicotine and non-
nicotine enriched e-cigarettes is shown in Table 2. E-cigarettes with nicotine were more effec-
tive for smoking cessation than e-cigarettes without nicotine. Pooled data from the two includ-
ed RCTs showed a statistically significant benefit of nicotine filled e-cigarettes compared to
those without nicotine (pooled Risk Ratio 2.29, 95% CI 1.05 to 4.97). Pooled RR is shown in
Fig 2, where the location of the diamond represents the estimated effect size, being statistically
Table 2. Characteristics of the two randomised controlled trails included in the meta-analysis that assessed the efficacy of e-cigarettes with and
without nicotine for smoking cessation.
Authors, year, study
design
e-cigarettes with nicotine e-cigarettes without nicotine RR (95%
CIs)
SE (log
RR)
M-H
weight
Stopped
smoking (n)
Continued
smoking (n)
Stopped
smoking (n)
Continued
smoking (n)
Bullen et al, 2013, RCT 21 268 3 70 1.77
(0.5–5.8)
0.6 47.3
Caponnetto et al, 2013,
RCT
22 178 4 96 2.75
(0.9–7.8)
0.53 52.7
RCT: randomized controlled trial, RR: relative risk, CIs: conﬁdence intervals, SE: standard error, M-H: Mantel–Haenszel
doi:10.1371/journal.pone.0122544.t002
Fig 2. Forest Plot of the effectiveness of e-cigarettes with and without nicotine in smoking cessation.
doi:10.1371/journal.pone.0122544.g002
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significant as it is larger than 1, and the width represents its precision also depicted by the con-
fidence interval. None of the RCTs was heterogeneous (I2 = 0.0%, P = 0.6). Based on these find-
ings, only e-cigarettes with nicotine were considered in the subsequent analyses.
Association between the use of e-cigarettes and smoking cessation
Subjects with complete information on smoking cessation (i.e., those who had information on
smoking cessation at the end of at least six months of follow up) were eligible to be included in
the meta-analysis. Of the original samples (n = 3,865 men and n = 3,686 women) reported in
the six studies, a total sample of 1,242 was meta-analysed. (Table 3)The latter had a weighted
average age of 41.5 (SD 13.9) years with a male to female proportion of 1.4, and an average
daily cigarette consumption of 16.2 cigarettes per day. Of the 1,242 smokers who reported
using nicotine enriched e-cigarettes, 224 (18%) reported complete smoking cessation after a
minimum 6-month use of e-cigarettes.
Pooled data from two RCTs, two cohort and two cross-sectional studies on the association of
nicotine enriched e-cigarettes with smoking cessation revealed a statistically significant effect
with an overall pooled Effect Size of 0.20 (95% CI 0.11 to 0.28) as shown in the forest plot
(Fig 3). As expected, there was considerable heterogeneity among the studies (I2 = 93.4%,
p<0.001). A meta-regression model showed that 98% of this heterogeneity was caused by the re-
search study design, and the variation in the proportion of males to females in each of the in-
cluded studies. Running the analyses separately by study design showed similar significant
findings (Table 4). However, the pooled effect size derived from the RCTs was smaller than
those observed in observational studies. Available data did not allow us to conduct the analyses
by gender. A further stratified analysis was conducted by smoking abstinence verification meth-
od. The two RCTs and one cohort study verified cessation using biochemical methods.[20–22]
The pooled ES of these three studies was 0.09 (0.06, 0.11). These three studies were not heteroge-
neous, I2 = 20%, P = 0.3. In the remaining studies, abstinence was self-reported with a pooled
ES of 0.24 (0.21, 0.27). Studies with self-reported data were heterogeneous (I2 = 88%, p<0.001).
E-cigarettes for smoking reduction
A qualitative analysis was conducted to determine whether use of e-cigarette reduced cigarette
consumption (rather than cessation) among the current smokers. All studies reported substan-
tial rates of smoking reduction among participants (Table 1).[20–25] Three studies reported
>50% reduction in daily cigarette consumption.[20, 21, 23]
Table 3. Proportion of smoking quitters in nicotine enriched e-cigarette users by study.
Authors, year Study design Total sample (N) Stopped smoking (n) Proportion (95% CIs) SE Weight#
Brown et al, 2014 Cross sectional 464 93 0.20 (0.16, 0.24) 0.02 18.8
Bullen et al, 2013 RCT 289 21 0.07 (0.04, 0.10) 0.02 19
Caponnetto et al, 2013 RCT 200 22 0.11 (0.07, 0.15) 0.02 18.5
Etter et al, 2013 Cohort 35 16 0.46 (0.29, 0.62) 0.08 11
Polosa et al, 2013 Cohort 40 5 0.12 (0.02, 0.23) 0.05 15
Siegel et al, 2011 Cross sectional 214 67 0.31 (0.25, 0.38) 0.03 17.6
RCT: randomized controlled trial, CIs: conﬁdence intervals, SE: standard error
# Weight: the weight was based on a random effects model using DerSimonian and Laird method
doi:10.1371/journal.pone.0122544.t003
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Quality assessment
Risk of bias in the included studies was evaluated using specific quality assessment tools and com-
pleted by two researchers independently. Potential bias was accounted for in 57% of all items as-
sessed in all studies, not accounted for in 24%, and in the remaining 19% such bias was either not
applicable or hard to assess due to missing information. Percent agreement between the assessors
was 78%, with a Kappa coefficient 0.62 (95% CI 0.50–0.69) showing substantial agreement.
Fig 3. Forest Plot of the association between nicotine-enriched e-cigarettes and smoking cessation.
doi:10.1371/journal.pone.0122544.g003
Table 4. Pooled proportion of smoking quitters among nicotine enriched e-cigarettes by study design: fixed effects meta-analysis model.
Study design Pooled ES (95% CIs) I-squared (variation in ES attributable to heterogeneity) Heterogeneity chi-squared
RCTs 0.08 (0.06, 0.11) 48.20% p = 0.165
Bullen et al, 2013
Caponnetto et al, 2013
Cohort studies 0.22 (0.02, 0.23) 91.10% p = 0.001
Etter et al, 2013
Polosa et al, 2013
Cross sectional studies 0.23 (0.20, 0.26) 89.40% p = 0.002
Brown et al, 2014
Siegel et al, 2011
doi:10.1371/journal.pone.0122544.t004
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Two RCTs had limited risk of bias.[20, 21] In the study by Bullen et al. there was a risk of se-
lection bias due to recruitment via community newspapers and being unable to blind partici-
pants receiving intervention.[20] The study by Caponnetto et al. was similarly at risk of
selection bias due to recruitment via local newspapers. This study also had a loss-to-follow-up
of 39%, which is not unusual for other studies of smokers who were unwilling to quit. Further-
more, since those participants were treated as failures according to intention-to-treat analysis,
reported cessation rates would, if anything, have been underestimated.[21]
Four observational studies were at risk of selection bias as they either used selected groups
as participants or had low response rates to recruitment methods.[22–25] The one possible ex-
ception to this is the study by Brown et al. which included participants from a large-scale na-
tional sampling survey. Those four studies also used self-reporting as the predominant method
to record exposure, making them susceptible to information bias.[22–25] This bias was mini-
mised in the study by Polosa et al., which used validated means (eCO) to verify outcomes ob-
jectively.[23]
Discussion
This systematic review and meta-analysis indicates an association between the use of nicotine-
enriched e-cigarettes and smoking cessation. We also report that e-cigarettes containing nico-
tine are more effective at aiding smoking cessation than e-cigarettes without nicotine, and that
e-cigarettes of both types may help ongoing smokers by reducing the number of tobacco ciga-
rettes they use. The association between the use of e-cigarettes and smoking cessation was con-
sistently observed in all included studies, also seen in different study designs, and abstinence
verification method. Studies that relied on a more objective biochemical abstinence verification
method had a lower pooled effect size than the studies that had self-reported information.
Nonetheless, the effect sizes in each verification method remained statistically significant. Our
results indicate that nicotine enriched e-cigarettes may prove to be a useful smoking
cessation method.
We compared findings from this meta-analysis to cessation rates known to be achievable
with existing NRTs. Two studies reported that the 12-month quit rate achieved using NRTs
was approximately 10%, and would not exceed this level in the longer term.[3, 4] Our meta-
analyses demonstrated a higher smoking cessation rate of 20% achieved with e-cigarettes, sug-
gesting that factors beyond nicotine replacement alone may contribute to smoking cessation.
[22] A feasible explanation for this is that e-cigarettes closely mimic the behavioural and aes-
thetic aspects of smoking, whereby the instinctive physical behaviours and cue responses that
smokers are accustomed to are satisfied alongside their pharmacological needs. This concept
has been elucidated in a qualitative study, in which users cite multiple non-pharmacological
reasons for their satisfaction with e-cigarettes.[32] This includes sensory and behavioural simu-
lation of smoking, as described by Caponnetto et al. in a study using a nicotine-free inhalator
to demonstrate the impact of handling and manipulation in promoting smoking cessation.[33]
Non-pharmacological drivers for e-cigarette users’ satisfaction included the social benefits
of being part of a ‘vaping’ community and counteracting the negative stigma attached to
smoking.[32]
Studies investigating patterns of e-cigarette consumption and user beliefs have similarly
found non-pharmacological reasons for use and satisfaction.[10, 34, 35] These include finan-
cial reasons (as e-cigarettes are cheaper than tobacco), a perception that e-cigarettes are less
harmful than tobacco and the ability to use them in places where smoking is banned.[10, 34,
35] Smokers may be attracted to and satisfied with e-cigarettes for these reasons beyond any
contribution to smoking cessation. This would explain our finding of comparable cessation
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rates regardless of intention to quit smoking, and for higher cessation rates than those reported
by studies investigating NRTs.[3, 4]
Another key finding of our study is that use of e-cigarettes was associated with a reduction
in the number of cigarettes used, which is important in light of the substantial body of evidence
demonstrating that gradual reduction in cigarette consumption aids future quit attempts.[36–
38] This indicates a potential role for e-cigarettes in tobacco harm reduction programs, in addi-
tion to a possible role as an alternative smoking cessation tool. It also suggests that in these
cases at least, dual use of e-cigarettes does not necessarily perpetuate or exacerbate smokers’ to-
bacco addiction and use, as some public health researchers have warned.
In analysing our findings we sought to examine the effect of potential confounders, includ-
ing study design and smokers’ intention to quit smoking. We found that the positive associa-
tion between use of nicotine-enriched e-cigarettes and smoking cessation was not affected by
study designs. When meta-analyses were calculated according to study designs, the results re-
mained significant within each study type. However, the pooled effect size derived from the
RCTs was smaller than that found in either cohort or cross-sectional studies. Cessation rates
were lower in all of those three studies, where biochemical abstinence verification methods
were used.[20, 21, 23] Smokers’ intention to quit did not appear to affect this positive associa-
tion. However, we note that, unlike traditional RCTs, these studies did not investigate the effect
of a medication on a disease state, but rather investigated the use of a non-medication interven-
tion (e-cigarettes) on a behaviour (smoking).
This review represents the most comprehensive evidence on e-cigarettes currently available,
and provides important and timely information for regulatory authorities and policymakers.
To date, the Food and Drug Administration (FDA) in the US and parliaments in Europe and
the UK have been under pressure to decide how strictly to regulate e-cigarettes, but devoid of
availability of substantial evidence regarding their cessation-related benefits versus safety or
addiction-related drawbacks.[39–41] Our findings indicate that e-cigarettes may be an effective
alternate smoking cessation tool will provide timely evidence to help informing this important
regulatory debate. Our findings may also provide important updates to other stakeholders, in-
cluding the wider research community and healthcare providers. Importantly, we note that the
long term health effects of e-cigarettes use are yet to be examined.
Limitations of this review include the paucity of available studies, biases within existing
studies, and their heterogeneity and variable quality. Studies were variously affected by small
sample sizes and methodological variation in data collection, rendering them susceptible to
varying degrees of selection and information bias. Furthermore, whilst we were able to com-
ment on the efficacy of nicotine e-cigarettes vs. non-nicotine e-cigarettes for smoking cessation,
we were unable to comment on the efficacy of e-cigarettes vs. other interventions for cessation,
given the lack of comparator groups in the studies included in this meta-analysis. Similarly,
since the pooled effect size derived from the RCTs was considerably smaller than those ob-
served in observational studies, the overall effect size from all studies combined may have
been overestimated.
This review highlights the need for further research on e-cigarettes. The available data did
not allow us to conduct sub analysis by gender which is an important factor. It is important to
explore gender-related heterogeneity between studies, so it can be determined whether the
overall trend differs according to this factor. Large-scale, randomised trials are required to vali-
date our study findings, and re-confirm the association between e-cigarette use and smoking
cessation. It is imperative that the safety and contents of e-cigarettes also need to be investigat-
ed and confirmed if they are to be used as smoking cessation aids or in tobacco harm reduction
programs. Finally, a wider cost-effectiveness analysis of the devices, weighing up the various
cessation and harm reduction benefits against any safety or other concerns would be highly
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valuable from a public health perspective. If the safety of e-cigarettes is proven, e-cigarettes
may assist healthcare providers to address smoking cessation challenges more effectively.
Conclusions
This systematic review and meta-analyses assessed the findings of six studies which reported
smoking cessation after using e-cigarettes. We found an association between nicotine-enriched
e-cigarette use and smoking cessation, suggesting that the devices may be an effective alterna-
tive smoking cessation method. We also found that use of e-cigarettes was also associated with
a reduction in the number of cigarettes used, suggesting they may also have a role in tobacco
harm reduction programs. To our knowledge, this is the most comprehensive evidence to date
on this issue, and while there are a number of important implications for further research,
these findings provide timely information to inform regulatory strategies.
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